These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 37641099)

  • 41. The Dose Response: Perceptions of People Living with HIV in the United States on Alternatives to Oral Daily Antiretroviral Therapy.
    Dubé K; Eskaf S; Evans D; Sauceda J; Saberi P; Brown B; Averitt D; Martel K; Meija M; Campbell D; Barr L; Kanazawa J; Perry K; Patel H; Luter S; Poteat T; Auerbach JD; Wohl DA
    AIDS Res Hum Retroviruses; 2020 Apr; 36(4):324-348. PubMed ID: 31608651
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Greater burden of chronic comorbidities and co-medications among people living with HIV versus people without HIV in Japan: A hospital claims database study.
    Ruzicka DJ; Imai K; Takahashi K; Naito T
    J Infect Chemother; 2019 Feb; 25(2):89-95. PubMed ID: 30396821
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Preferences for long-acting pre-exposure prophylaxis among gay, bisexual and other men who have sex with men in Taiwan: findings from the 2021 HEART Survey.
    Hsu JH; Ku SW; Chen TW; Li CW; Huang P; Wu HJ; Bourne A; Strong C
    J Int AIDS Soc; 2023 Sep; 26(9):e26163. PubMed ID: 37675767
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Acceptance Rate and Reasons for Rejection of Long Acting Injectable Antiretrovirals.
    Feihel D; Spier D; Stevens T; Stefanov DG; Ahmadi L
    AIDS Behav; 2023 Jul; 27(7):2370-2375. PubMed ID: 36576664
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-Acting Injectable Antiretroviral Treatment Acceptability and Preferences: A Qualitative Study Among US Providers, Adults Living with HIV, and Parents of Youth Living with HIV.
    Simoni JM; Beima-Sofie K; Mohamed ZH; Christodoulou J; Tapia K; Graham SM; Ho R; Collier AC
    AIDS Patient Care STDS; 2019 Mar; 33(3):104-111. PubMed ID: 30844308
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression.
    Swindells S; Andrade-Villanueva JF; Richmond GJ; Rizzardini G; Baumgarten A; Masiá M; Latiff G; Pokrovsky V; Bredeek F; Smith G; Cahn P; Kim YS; Ford SL; Talarico CL; Patel P; Chounta V; Crauwels H; Parys W; Vanveggel S; Mrus J; Huang J; Harrington CM; Hudson KJ; Margolis DA; Smith KY; Williams PE; Spreen WR
    N Engl J Med; 2020 Mar; 382(12):1112-1123. PubMed ID: 32130809
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Perceptions of Long-Acting Injectable Antiretroviral Treatment Regimens in a United States Urban Academic Medical Center.
    Koren DE; Fedkiv V; Zhao H; Kludjian G; Bettiker RL; Tedaldi E; Samuel R
    J Int Assoc Provid AIDS Care; 2020; 19():2325958220981265. PubMed ID: 33327851
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Potential drug-drug interactions due to concomitant medicine use among people living with HIV on antiretroviral therapy in Australia.
    de Oliveira Costa J; Lau S; Medland N; Gibbons S; Schaffer AL; Pearson SA
    Br J Clin Pharmacol; 2023 May; 89(5):1541-1553. PubMed ID: 36434744
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Background factors in people living with HIV in Japan who switch to cabotegravir plus rilpivirine: A pilot study.
    Adachi E; Ikeuchi K; Koga M; Yotsuyanagi H
    J Infect Chemother; 2023 Jan; 29(1):109-111. PubMed ID: 36116718
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Patient preferences and health state utilities associated with the treatment process of antiretroviral therapy for people living with HIV.
    Matza LS; Howell TA; Chounta V; van de Velde N
    Qual Life Res; 2023 Feb; 32(2):531-541. PubMed ID: 36512302
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Co-medications and Drug-Drug Interactions in People Living with HIV in Turkey in the Era of Integrase Inhibitors.
    Yeşilbağ Z; Şengül Eİ; Şenoğlu S; Aydın ÖA; Karaosmanoğlu HK
    Curr HIV Res; 2020; 18(6):415-425. PubMed ID: 32787762
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Preferences of People Living with HIV for Long-Acting Antiretroviral Treatment in Germany: Evidence from a Discrete Choice Experiment.
    Emmert M; Rohrbacher S; Jahn J; Fernando K; Lauerer M
    Patient; 2023 Sep; 16(5):537-553. PubMed ID: 37436659
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Compassionate use of long-acting cabotegravir plus rilpivirine for people living with HIV-1 in need of parenteral antiretroviral therapy.
    D'Amico R; Cenoz Gomis S; Moodley R; Van Solingen-Ristea R; Baugh B; Van Landuyt E; Van Eygen V; Min S; Cutrell A; Foster C; Chilton D; Allard SD; Ruiter A
    HIV Med; 2023 Feb; 24(2):202-211. PubMed ID: 35945163
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prevalence and factors associated with HIV treatment non-adherence among people living with HIV in three regions of Cameroon: A cross-sectional study.
    Buh A; Deonandan R; Gomes J; Krentel A; Oladimeji O; Yaya S
    PLoS One; 2023; 18(4):e0283991. PubMed ID: 37014900
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Longitudinal study on adherence, treatment satisfaction, and effectiveness of once-daily versus twice-daily antiretroviral therapy in a Spanish cohort of HIV-infected patients (CUVA study)].
    Viciana P; Rubio R; Ribera E; Knobel H; Iribarren JA; Arribas JR; Pérez-Molina JA;
    Enferm Infecc Microbiol Clin; 2008 Mar; 26(3):127-34. PubMed ID: 18358210
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Advances in long-acting slow effective release antiretroviral therapies for treatment and prevention of HIV infection.
    Ullah Nayan M; Sillman B; Hasan M; Deodhar S; Das S; Sultana A; Thai Hoang Le N; Soriano V; Edagwa B; Gendelman HE
    Adv Drug Deliv Rev; 2023 Sep; 200():115009. PubMed ID: 37451501
    [TBL] [Abstract][Full Text] [Related]  

  • 57. "Lighten This Burden of Ours": Acceptability and Preferences Regarding Injectable Antiretroviral Treatment Among Adults and Youth Living With HIV in Coastal Kenya.
    Simoni JM; Beima-Sofie K; Wanje G; Mohamed ZH; Tapia K; McClelland RS; Ho RJY; Collier AC; Graham SM
    J Int Assoc Provid AIDS Care; 2021; 20():23259582211000517. PubMed ID: 33685272
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Factors Associated with Treatment Satisfaction Among People Living with HIV in Japan and Other Selected Countries: Examination of the Intertwined Roles of Medication, Patient, and Provider Characteristics.
    Koga I; Wakatabe R; Okamoto N; Sasai A; Kambara K; Maldonado A; de Los Rios P; Okoli C
    AIDS Behav; 2022 May; 26(5):1633-1651. PubMed ID: 34870772
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Patient and Physician Preferences for Regimen Attributes for the Treatment of HIV in the United States and Canada.
    Gelhorn H; Garris C; Arthurs E; Spinelli F; Cutts K; Chua GN; Collacott H; Lebouché B; Lowman E; Rice H; Heidenreich S
    J Pers Med; 2022 Feb; 12(3):. PubMed ID: 35330334
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
    Jaeger H; Overton ET; Richmond G; Rizzardini G; Andrade-Villanueva JF; Mngqibisa R; Hermida AO; Thalme A; Belonosova E; Ajana F; Benn PD; Wang Y; Hudson KJ; Español CM; Ford SL; Crauwels H; Margolis DA; Talarico CL; Smith KY; van Eygen V; Van Solingen-Ristea R; Vanveggel S; Spreen WR
    Lancet HIV; 2021 Nov; 8(11):e679-e689. PubMed ID: 34648734
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.